Evidence map›Paper›PMID 37534543›Full record

ArticleHaematologica2024

Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization.

Marion Ciudad, Sethi Ouandji, Baptiste Lamarthée, Claudie Cladière, Thibault Ghesquière, Martin Nivet, Marine Thébault, Romain Boidot, Agnès Soudry-Faure, Sandy Chevrier and 12 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02158195 (Immunopathology of Autoimmune Hemolytic Anemia), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02158195 completednot on this map

Immunopathology of Autoimmune Hemolytic Anemia: an Open, Prospective and Multicenter Study

TypeobservationalSponsorCentre Hospitalier Universitaire DijonRan2013 to 2018Enrolled27ConditionsAutoimmune Hemolytic AnemiaArmsblood samples
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Autoimmune haemolytic anaemias.Nature reviews. Disease primers · 2024
    Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Marion CiudadDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Sethi OuandjiDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Baptiste LamarthéeUniversité de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Claudie CladièreDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Thibault GhesquièreDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Martin NivetDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Marine ThébaultDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Romain BoidotUnit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
Agnès Soudry-FaureDepartment of Clinical Research and Innovation (DRCI), Clinical Research Unit-Methodological Support Network (USMR), Dijon Bourgogne University Hospital, Dijon.
Sandy ChevrierUnit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
Corentin RichardUnit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
Thibault MailletDepartment of Internal Medicine - Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale - F-71000 Macon.
François MaurierDepartment of Internal Medicine, Groupe Hospitalier UNEOS - F-57000 Metz.
Hélène GreigertDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Coraline GenetUniversité de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
André RamonUniversité de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Malika TradUniversité de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Valérie PredanDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon.
Philippe SaasUniversité de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Maxime SamsonDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Bernard BonnotteDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Sylvain AudiaDepartment of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon. sylvain.audia@u-bourgogne.fr.
Inserm · FRUniversité de Bourgogne · FRCentre Georges François Leclerc · FRMaison des Sciences sociales et des Humanités de Dijon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Warm autoimmune hemolytic anemia (wAIHA) is a rare acquired autoimmune disease mediated by antibodies targeting red blood cells. The involvement of CD4 T-helper cells has been scarcely explored, with most findings extrapolated from animal models. Here, we performed quantification of both effector T lymphocytes (Teff) and regulatory T cells (Treg), associated with functional and transcriptomic analyses of Treg in human wAIHA. We observed a shift of Teff toward a Th17 polarization concordant with an increase in serum interleukin-17 concentration that correlates with red blood cell destruction parameters, namely lactate dehydrogenase and bilirubin levels. A decrease in circulating Treg, notably effector Treg, associated with a functional deficiency, as represented by their decrease capability to inhibit Teff proliferation, were also observed. Treg deficiency was associated with a reduced expression of Foxp3, the master transcription factor known to maintain the Treg phenotype stability and suppressive functions. Transcriptomic profiling of Treg revealed activation of the tumor necrosis facto (TNF)-α pathway, which was linked to increased serum TNF-α concentrations that were twice as high as in controls. Treg transcriptomic profiling also suggested that post-translational mechanisms possibly accounted for Foxp3 downregulation and Treg dysfunctions. Since TNF-α participates in the rupture of immune tolerance during wAIHA, its inhibition could be of interest. To this end, the effects of fostamatinib, a SYK inhibitor, were investigated in vitro, and we showed that besides the inhibition of erythrocyte phagocytosis by monocytes, fostamatinib is also able to dampen TNF-α production, thus appearing as a promising multitargeting therapy in wAIHA (clinicaltrials gov. Identifier: NCT02158195).

Indexed as

AminopyridinesAnemia, Hemolytic, AutoimmuneMorpholinesPyrimidinesT-Lymphocytes, RegulatoryAnimalsForkhead Transcription FactorsHumansTh17 CellsTumor Necrosis Factor-alphaAminopyridinesForkhead Transcription FactorsfostamatinibMorpholinesPyrimidinesTumor Necrosis Factor-alpha

Identifiers

PMID37534543
PMCPMC10828774
OpenAlexW4385514610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.